Keyphrases
Receptor Agonist
100%
A1 Receptor
100%
Glucagon-like
100%
Antidiabetic
100%
Weight Change
100%
Health System Data
100%
Sodium-glucose Cotransporter 2 Inhibitors (SGLT2i)
100%
Dipeptidyl peptidase-4 (DPP-4)
71%
Sulfonylurea
57%
Antidiabetic Drugs
42%
Massive Weight Loss
42%
5% Weight Loss
28%
New Antidiabetic Drugs
28%
Confidence Interval
14%
Health Systems
14%
Obesity
14%
Body Mass Index
14%
Clinical Trials
14%
Weight Loss
14%
Patients with Diabetes
14%
Propensity Score
14%
Overweight or Obesity
14%
Real-world Effectiveness
14%
Real-world Practice
14%
Medicine and Dentistry
Health System
100%
Antidiabetic Agent
100%
Body Weight Change
100%
Glucagon-Like Peptide-1 Agonist
100%
Sodium Glucose Cotransporter 2 Inhibitor
100%
Dipeptidyl Peptidase-4 Inhibitor
71%
Sulfonylurea
57%
Drug Therapy
42%
Body Mass Index
14%
Patient with Diabetes
14%
Clinical Trial
14%
Obesity
14%
Patient with Obesity
14%
Patient with Overweight
14%
Pharmacology, Toxicology and Pharmaceutical Science
Antidiabetic Agent
100%
Glucagon Like Peptide 1 Receptor Agonist
100%
Sodium Glucose Cotransporter 2 Inhibitor
100%
Dipeptidyl Peptidase IV Inhibitor
71%
Sulfonylurea
57%
Obesity
28%
Clinical Trial
14%